You may qualify for one of our clinical trials! For more information about joining a clinical trial, please email research@
You Deserve the Best in Advanced Orthopedic Care
Clinical Trials for Orthopedic Pain
CURRENTLY RECRUITING
STACI - iFUSE TORQ for the treatment of Sacroiliac Joint Dysfunction
This is a post-market clinical study to evaluate the effectiveness of the iFuse TORQ, a device that has been cleared by the U.S. Food and Drug Administration for SI joint fusion, to treat sacroiliac joint pain. Possible benefits include faster or more complete pain relief compared with non-surgical treatment. This study involves a total of 5 visits at our site over the course of 24 months, and includes a stipend for each visit.
CURRENTLY RECRUITING
Spine BioPharma MODEL - Clinical Trial for Degenerative Disc Disease and Low Back Pain
This is a Phase 3 clinical trial of the investigational drug SB-01 for the treatment of Lumbar Degenerative Disc Disease. SB-01 is a peptide administered by an injection into the spinal disc. Possible benefits include the reduction of pain-related disability associated with degenerative disc disease. This study involves a total of 7 visits at our site over the course of 12 months and includes a stipend for each visit.
See if you’re eligible: Model Study Pre-Screening
CURRENTLY RECRUITING
JointStem - Cellular Clinical Trial for Knee Osteoarthritis
This is a Phase 2b/3a clinical trial study of investigational drug JointStem in participants experiencing moderate to severe pain due to osteoarthritis of the knee. JointStem is an autologous adipose derived cellular injection to the affected knee. The possible benefits include increased mobility in the knee and reduction in pain symptoms. This study involves a total of 8 visits at our site over the course of 1 year, and includes a stipend for each visit.
See if you’re eligible: JointStem Knee OA Pre-Screening
CURRENTLY RECRUITING
TissueGene TG-C - Cellular Clinical Trial for Knee Osteoarthritis
This is a Phase 3 clinical trial study of investigational drug TG-C in participants experiencing chronic pain from knee osteoarthritis. TG-C is to be administered by a single intra-articular injection to the damaged joint area. Possible benefits include delayed progression of knee OA, longer knee joint preservation, and improved quality of life. The study will include 11 follow-up visits over the course of 24 months, and includes a stipend for each visit.
See if you’re eligible: TissueGene Knee OA Pre-Screening
